Treatment with BAY 1816032, an inhibitor of BUB1, or knockdown of BUB1 could suppress the biological activity of OS related to cell proliferation, apoptotic tolerance, migration and invasion in vitro and tumour growth in vivo, with the involvement of PI3K/Akt and ERK pathways. The gene discussed is AKT1; the disease is neoplasm.